[HTML][HTML] Searching for the role of primary prophylaxis in preventing inhibitor development in hemophilia A
A Coppola, A Tagliaferri, M Franchini - Journal of Thrombosis and …, 2012 - jthjournal.org
Approximately 30% of individuals with severe hemophilia A generate antibodies (inhibitors)
against therapeutically administered factor VIII (FVIII), typically during the first 20 exposure
days [1]. Inhibitor development remains the most serious complication of treatment of
hemophilia, as the safe and effective standard of care, particularly prophylaxis in children, is
precluded. Despite improvements in treatment of bleeding with by-passing agents [2] and
recent implementation of prophylactic regimens [3], patients with inhibitors experience …
against therapeutically administered factor VIII (FVIII), typically during the first 20 exposure
days [1]. Inhibitor development remains the most serious complication of treatment of
hemophilia, as the safe and effective standard of care, particularly prophylaxis in children, is
precluded. Despite improvements in treatment of bleeding with by-passing agents [2] and
recent implementation of prophylactic regimens [3], patients with inhibitors experience …